Article · 2016
Editorial Board Member
Manchao Zhang
Senior Research Associate, The Ohio State University, USA
About
As published by the journal they serve.
Manchao Zhang has started working on cancer immunotherapy in the 1990s, received rigorous immunological training from Dr. John E. Coligan at NIAID/NIH, dissected the molecular mechanism of action of the TNF super-family member, Light, for the first time reported that a small molecule natural compound as an orally available Bcl-2 family member inhibitor anticancer drug, identified so far the most potent Grb2 SH2 domain antagonist small molecule inhibitors, validated two dozens of anticancer drug targets. He also served as reviewers for a number of peer-reviewed journals and funding agencies.
Research interests
Journals they serve
The seats these journals name them in.
- Immunotherapy: Open AccessEditorial Board Member
Articles we hold
Articles in the journals they serve whose byline carries this name.
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.
